ATG16L1 and inflammatory bowel disease: The clinical relevance of this mechanism is underscored by human genetic studies associating ATG16L1 polymorphisms (e.g., T300A) with exaggerated IL-1β and IL-6 production in inflammatory bowel disease [30],[42],[43].